CONCLUSIONS At least one PROM with some evidence for aspects of validity and reliability was available for six of the eight m and atory domains of the PsA COS
BACKGROUND An up date d psoriatic arthritis ( PsA ) core outcome set ( COS ) for r and omized controlled trials ( RCTs ) was endorsed at the Outcome Measures in Rheumatology ( OMERACT ) meeting in 2016 .
OBJECTIVES To synthesize the evidence on measurement properties of patient reported outcome measures ( PROMs ) for PsA and thereby contribute to development of a PsA core outcome measurement set ( COMS ) as described by the OMERACT Filter 2.0 .
Minimally Important Difference of Health Assessment Questionnaire in Psoriatic Arthritis: Relating Thresholds of Improvement in Functional Ability to Patient-rated Importance and Satisfaction
Objective . To evaluate changes in function as measured by Health Assessment Question naire Disability Index ( HAQ-DI ) and the meaningfulness of the changes , in importance and satisfaction , in patients with psoriatic arthritis ( PsA ) . Methods . HAQ-DI was assessed at baseline and at Weeks 4 , 12 , and 24 in a r and omized double-blind study of 205 patients with active PsA receiving etanercept 25 mg twice weekly or placebo .  Concurrently , patients rated the importance of and satisfaction with their change in function on a 7-point scale ( 1 = not at all important/satisfied ; 7 = extremely important/satisfied ) . Mean HAQ-DI improvement corresponding to ratings of minimally ( 2–3 ) or very ( 6–7 ) important or satisfied was determined using a posthoc linear mixed-model analysis . Patient importance ratings were used as an anchor to estimate minimally important difference ( MID ) for HAQ-DI ; distribution-based estimates were also calculated . Results . A total of 161 patients ( 69 placebo ; 92 etanercept ) had ≥ 1 HAQ-DI scores showing improvement from baseline and a corresponding importance or satisfaction rating . HAQ-DI improvements corresponding to importance scale ratings of 2 or 3 were 0.335 ( 95 % CI 0.214 , 0.455 ) and 0.360 ( 95 % CI 0.263 , 0.456 ) , respectively , suggesting an MID of about 0.35 . HAQ-DI improvements corresponding to satisfaction scale ratings of 2 and 3 were 0.293 ( 95 % CI 0.230 , 0.357 ) and 0.360 ( 95 % CI 0.307 , 0.413 ) . For a given change in HAQ-DI , nearly two-thirds of patients indicated a lower rating for satisfaction than for importance . This trial was registered in the Clinical Trials.gov registry ( NCT00317499 ) . Conclusion . Our study suggests the MID for HAQ-DI in PsA is about 0.35 . The results may also provide insight into patient satisfaction with changes in function and expectations for therapy
CONCLUSIONS At least one PROM with some evidence for aspects of validity and reliability was available for six of the eight m and atory domains of the PsA COS
BACKGROUND An up date d psoriatic arthritis ( PsA ) core outcome set ( COS ) for r and omized controlled trials ( RCTs ) was endorsed at the Outcome Measures in Rheumatology ( OMERACT ) meeting in 2016 .
OBJECTIVES To synthesize the evidence on measurement properties of patient reported outcome measures ( PROMs ) for PsA and thereby contribute to development of a PsA core outcome measurement set ( COMS ) as described by the OMERACT Filter 2.0 .